Is FTRE or DNA more profitable?

Fortrea has a net margin of -3.18% compared to Ginkgo Bioworks' net margin of -259.96%. Fortrea's return on equity of 10.72% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Fortrea -3.18% 10.72% 2.17% Ginkgo Bioworks -259.96% -60.27% -26.88%

Ginkgo Bioworks (DNA) Competitors

$6.80 -0.44 (-6.12%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$6.81 +0.02 (+0.22%)

As of 08/14/2026 08:00 PM Eastern

Compare

DNA vs. TWST, ALMR, FTRE, BLFS, and MRVI

Should you buy Ginkgo Bioworks stock or one of its competitors? Ginkgo Bioworks's main competitors and comparable companies include Twist Bioscience (TWST), Alamar Biosciences (ALMR), Fortrea (FTRE), BioLife Solutions (BLFS), and Maravai LifeSciences (MRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Ginkgo Bioworks compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Twist Bioscience currently has a consensus target price of $98.30, indicating a potential downside of 17.10%. Ginkgo Bioworks has a consensus target price of $7.00, indicating a potential upside of 2.99%. Given Ginkgo Bioworks' higher probable upside, analysts clearly believe Ginkgo Bioworks is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Ginkgo Bioworks	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Twist Bioscience has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market.

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$431.80M	17.22	-$77.67M	-$2.22	N/A
Ginkgo Bioworks	$170.15M	2.69	-$312.76M	-$5.01	N/A

Twist Bioscience has a net margin of -31.66% compared to Ginkgo Bioworks' net margin of -259.96%. Twist Bioscience's return on equity of -28.64% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

In the previous week, Twist Bioscience had 13 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 13 mentions for Twist Bioscience and 0 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 0.63 beat Ginkgo Bioworks' score of 0.00 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Twist Bioscience	Positive
Ginkgo Bioworks	Neutral

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Twist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Alamar Biosciences?

Ginkgo Bioworks (NYSE:DNA) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ginkgo Bioworks presently has a consensus target price of $7.00, indicating a potential upside of 2.99%. Alamar Biosciences has a consensus target price of $31.80, indicating a potential downside of 4.10%. Given Ginkgo Bioworks' higher possible upside, equities analysts clearly believe Ginkgo Bioworks is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Alamar Biosciences has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -259.96%. Alamar Biosciences' return on equity of 0.00% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Alamar Biosciences	N/A	N/A	N/A

In the previous week, Alamar Biosciences had 17 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 17 mentions for Alamar Biosciences and 0 mentions for Ginkgo Bioworks. Alamar Biosciences' average media sentiment score of 0.57 beat Ginkgo Bioworks' score of 0.00 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Ginkgo Bioworks	Neutral
Alamar Biosciences	Positive

Alamar Biosciences has lower revenue, but higher earnings than Ginkgo Bioworks. Alamar Biosciences is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	2.69	-$312.76M	-$5.01	N/A
Alamar Biosciences	$100.42M	22.91	-$29.82M	-$1.74	N/A

Summary

Alamar Biosciences beats Ginkgo Bioworks on 10 of the 15 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Fortrea has a beta of 1.99, indicating that its stock price is 99% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market.

In the previous week, Fortrea had 11 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 11 mentions for Fortrea and 0 mentions for Ginkgo Bioworks. Fortrea's average media sentiment score of 0.96 beat Ginkgo Bioworks' score of 0.00 indicating that Fortrea is being referred to more favorably in the media.

Company	Overall Sentiment
Fortrea	Positive
Ginkgo Bioworks	Neutral

Fortrea has a net margin of -3.18% compared to Ginkgo Bioworks' net margin of -259.96%. Fortrea's return on equity of 10.72% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

Ginkgo Bioworks has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.68B	0.62	-$986.20M	-$0.91	N/A
Ginkgo Bioworks	$170.15M	2.69	-$312.76M	-$5.01	N/A

Fortrea currently has a consensus target price of $20.75, suggesting a potential upside of 19.18%. Ginkgo Bioworks has a consensus target price of $7.00, suggesting a potential upside of 2.99%. Given Fortrea's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortrea is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ginkgo Bioworks	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 0.7% of Fortrea shares are owned by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Fortrea beats Ginkgo Bioworks on 11 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to BioLife Solutions?

Ginkgo Bioworks (NYSE:DNA) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BioLife Solutions has lower revenue, but higher earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	2.69	-$312.76M	-$5.01	N/A
BioLife Solutions	$96.21M	17.81	-$4.59M	$1.16	30.23

Ginkgo Bioworks presently has a consensus target price of $7.00, indicating a potential upside of 2.99%. BioLife Solutions has a consensus target price of $31.38, indicating a potential downside of 10.54%. Given Ginkgo Bioworks' higher probable upside, equities analysts clearly believe Ginkgo Bioworks is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18

In the previous week, BioLife Solutions had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 4 mentions for BioLife Solutions and 0 mentions for Ginkgo Bioworks. BioLife Solutions' average media sentiment score of 0.52 beat Ginkgo Bioworks' score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Overall Sentiment
Ginkgo Bioworks	Neutral
BioLife Solutions	Positive

BioLife Solutions has a net margin of 53.29% compared to Ginkgo Bioworks' net margin of -259.96%. BioLife Solutions' return on equity of 2.70% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
BioLife Solutions	53.29%	2.70%	2.49%

Ginkgo Bioworks has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market.

Summary

BioLife Solutions beats Ginkgo Bioworks on 14 of the 17 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Maravai LifeSciences currently has a consensus target price of $6.25, indicating a potential upside of 9.65%. Ginkgo Bioworks has a consensus target price of $7.00, indicating a potential upside of 2.99%. Given Maravai LifeSciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Maravai LifeSciences is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ginkgo Bioworks	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Maravai LifeSciences has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market.

Maravai LifeSciences has a net margin of -37.07% compared to Ginkgo Bioworks' net margin of -259.96%. Maravai LifeSciences' return on equity of -15.70% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Maravai LifeSciences has higher revenue and earnings than Ginkgo Bioworks. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$208.78M	7.09	-$130.77M	-$0.52	N/A
Ginkgo Bioworks	$170.15M	2.69	-$312.76M	-$5.01	N/A

In the previous week, Maravai LifeSciences had 6 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 6 mentions for Maravai LifeSciences and 0 mentions for Ginkgo Bioworks. Maravai LifeSciences' average media sentiment score of 0.61 beat Ginkgo Bioworks' score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Maravai LifeSciences	Positive
Ginkgo Bioworks	Neutral

Summary

Maravai LifeSciences beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

Get Ginkgo Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNA vs. The Competition

Export

Metric	Ginkgo Bioworks	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$487.54M	$9.66B	$7.04B	$24.33B
Dividend Yield	N/A	1.46%	2.57%	3.68%
P/E Ratio	-1.36	60.32	268.81	30.78
Price / Sales	2.69	105.52	562.07	64.35
Price / Cash	N/A	26.25	70.48	32.80
Price / Book	1.09	37.50	12.91	6.82
Net Income	-$312.76M	$56.66B	$3.45B	$1.06B
7 Day Performance	-14.56%	0.30%	1.11%	0.54%
1 Month Performance	-24.62%	1.38%	1.33%	2.88%
1 Year Performance	-48.35%	17.34%	62.44%	19.08%

Ginkgo Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNA Ginkgo Bioworks	0.1973 of 5 stars	$6.80 -6.1%	$7.00 +3.0%	-47.3%	$487.54M	$170.15M	N/A	640
TWST Twist Bioscience	1.3517 of 5 stars	$124.88 +8.0%	$98.30 -21.3%	+311.1%	$7.25B	$376.57M	N/A	990	Insider Trade
ALMR Alamar Biosciences	1.0629 of 5 stars	$27.99 -1.7%	$30.00 +7.2%	N/A	$1.97B	$74.21M	N/A	222	News Coverage Earnings Report Analyst Forecast
FTRE Fortrea	3.9783 of 5 stars	$18.99 +3.0%	$20.75 +9.3%	+120.4%	$1.75B	$2.72B	N/A	14,300
BLFS BioLife Solutions	3.0749 of 5 stars	$34.64 -0.1%	$31.38 -9.4%	+38.5%	$1.69B	$96.21M	29.86	440	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DNA) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, ALMR, FTRE, BLFS, and MRVI

How does Ginkgo Bioworks compare to Twist Bioscience?

Summary

How does Ginkgo Bioworks compare to Alamar Biosciences?

Summary

How does Ginkgo Bioworks compare to Fortrea?

Summary

How does Ginkgo Bioworks compare to BioLife Solutions?

Summary

How does Ginkgo Bioworks compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, ALMR, FTRE, BLFS, and MRVI

How does Ginkgo Bioworks compare to Twist Bioscience?

Do analysts rate TWST or DNA?

Which has more risk & volatility, TWST or DNA?

Which has higher earnings and valuation, TWST or DNA?

Is TWST or DNA more profitable?

Does the media refer more to TWST or DNA?

Do insiders & institutionals believe in TWST or DNA?

Summary

How does Ginkgo Bioworks compare to Alamar Biosciences?

Do institutionals and insiders believe in DNA or ALMR?

Do analysts prefer DNA or ALMR?

Is DNA or ALMR more profitable?

Does the media favor DNA or ALMR?

Which has higher valuation and earnings, DNA or ALMR?

Summary

How does Ginkgo Bioworks compare to Fortrea?

Which has more risk & volatility, FTRE or DNA?

Does the media refer more to FTRE or DNA?

Is FTRE or DNA more profitable?

Which has preferable valuation and earnings, FTRE or DNA?

Do analysts prefer FTRE or DNA?

Do institutionals & insiders hold more shares of FTRE or DNA?

Summary

How does Ginkgo Bioworks compare to BioLife Solutions?

Do insiders and institutionals believe in DNA or BLFS?

Which has preferable valuation and earnings, DNA or BLFS?

Do analysts recommend DNA or BLFS?

Does the media prefer DNA or BLFS?

Is DNA or BLFS more profitable?

Which has more risk & volatility, DNA or BLFS?

Summary

How does Ginkgo Bioworks compare to Maravai LifeSciences?

Do analysts rate MRVI or DNA?

Which has more risk & volatility, MRVI or DNA?

Is MRVI or DNA more profitable?

Do insiders & institutionals believe in MRVI or DNA?

Which has stronger earnings and valuation, MRVI or DNA?

Does the media favor MRVI or DNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools